TGTatiana P. Gizatulina

Tatiana P. Gizatulina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatiana P. Gizatulina has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gender specifics in the long-term efficacy of primary catheter ablation for atrial fibrillation

    by A. V. Mamarina, T. P. Gizatulina, D. V. Belonogov, E. A. Gorbatenko

    Currently there is no clear evidence regarding the influence of gender on the effectiveness of catheter ablation (CA) in patients with atrial fibrillation (AF). The insufficient understanding of predictors of long-term CA outcomes necessitates further analysis of gender-specific characteristics. Aim : To identify predictors of late AF recurrences after CA in male and female patients. Material and Methods . This prospective study included 192 patients with symptomatic nonvalvular AF (116 men and 76 women; mean age 59.0 ± 6.7 years), predominantly with paroxysmal AF (78%). All patients underwent clinical and laboratory evaluation, including measurement of NT-proBNP, growth differentiation factor-15 (GDF-15), and soluble suppression of tumorigenicity-2 (sST2), as well as transthoracic and transesophageal echocardiography to exclude left atrial (LA) thrombosis. Electroanatomical mapping of the LA was performed in all patients with assessment of the area of low-voltage zones (LVZ), followed by radiofrequency circumferential pulmonary vein isolation. Prospective follow-up after the procedure was conducted at 3, 6, 12, and 18 months after completion of a 90-day blanking period. Results . The median follow-up duration was 14.0 (5; 36) months. The incidence of late AF recurrences did not differ between men and women (35.6% vs. 32.9%, p = 0.755). In men, late recurrences were associated with a history of myocardial infarction ( p = 0.042), sST2 levels > 36 ng/mL ( p = 0.034), and early AF recurrences ( p < 0.001). In women, significant predictors included left ventricular (LV) end-diastolic volume index ( p = 0.001), LV end-systolic volume index ( p = 0.008), higher functional class of chronic heart failure ( p = 0.026), and early AF recurrences ( p = 0.024). According to Kaplan–Meier analysis, early AF recurrences were an unfavorable prognostic factor in both sexes; additionally, in women, an LV end-systolic volume index > 16 mL/m² and LA LVZ area > 20% were associated with worse outcomes, whereas in men, sST2 levels > 36 ng/mL were prognostically unfavorable. Conclusion . The study demonstrated significant sex-specific differences in predictors of late AF recurrences after primary CA. In women, markers of structural remodeling of the left heart chambers (increased LV end-systolic and end-diastolic volume indices, larger LA LVZ area) and clinical manifestations of heart failure play. But in men, sST2 levels above the threshold of 36 ng/mL are of primary importance. Early AF recurrences during the blanking period represent a common predictor of reduced freedom from AF in both sexes.

  • Open Access

    Mean Platelet Volume as a Predictor of Left Atrial Appendage Thrombus Resistance to Lysis in Patients With Atrial Fibrillation: Results of a 12-Month Follow-Up

    by Tatiana P. Gizatulina, Alfira V. Belokurova, Aleksandra V. Mamarina, Natalia Yu. Khorkova, Elena A. Gorbatenko

    Background: Left atrial appendage thrombosis (LAAT), a contraindication to catheter ablation (CA), is a major problem in patients with non-valvular atrial fibrillation (AF). This study aimed to investigate the dynamics of LAAT and identify the factors associated with resistance to LAAT resolution over a 12-month period. Methods: A total of 83 of the 2766 patients with AF who underwent transesophageal echocardiography (TEE) before CA (median age, 62 years; 49 men) participated in follow-up studies. All patients received oral anticoagulants (OACs) and underwent a general clinical examination, which included a complete blood count, biochemical tests, and transthoracic echocardiography. In total, 39 patients (47%) had paroxysmal AF, and 44 patients (53%) had persistent AF. Results: Patients were divided into two groups based on dynamic TEE monitoring: Group 1 (n = 45), comprising patients whose LAAT resolved within 12 months, and Group 2 (n = 38), consisting of patients whose LAAT persisted until the end of the follow-up study. No significant differences were observed in age, sex, and incidence of cardiovascular disease between the groups. However, Group 2 patients were more likely to administer beta-blockers, diuretics, and rivaroxaban at the start of the study. The OACs were altered in 65 patients due to the repeated detection of LAAT. Comparative analysis revealed that Group 2 patients had higher right atrial volume index, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, mean platelet volume (MPV), platelet distribution width, and platelet–large cell ratio. Multivariate logistic regression analysis was used to derive a prediction model for LAAT resistance, which included three independent predictors: diuretics intake (odds ratio (OR) 3.800, 95% confidence interval (CI) 1.281–11.275; p = 0.016), NT-proBNP level (OR 1.001, 95% CI 1.000–1.001; p = 0.015), and MPV (OR 1.892, 95% CI 1.056–3.387; p = 0.032). The receiver operating characteristic (ROC) analysis confirmed the good quality of the model: Area under the ROC curve (AUC) 0.789, specificity 72.7%, and sensitivity 73.3%. Conclusions: This study confirmed that approximately 47% LAAT remains resistant to lysis 1 year after initial detection in patients with AF, regardless of the use of OACs. To our knowledge, this is the first time that platelet morphofunctional parameters, particularly MPV, have been identified as predictors of LAAT lysis resistance, and further research in this direction is needed.

  • Open Access

    The possibilities of monitoring the effectiveness of anticoagulant therapy using a thrombodynamics test in patients with left atrial appendage thrombosis with non-valvular atrial fibrillation: clinical cases

    by N. Yu. Khorkova, T. P. Gizatulina, A. V. Belokurova, A. V. Mamarina, Н. Ю. Хорькова

    Clinical observations of the possibility of using the thrombodynamics test (TD) in comparison with standard hemostasis tests in patients with non-valvular atrial fibrillation (AF) and detected thrombosis of the left atrial appendage against the background constant oral anticoagulants are presented. It has been shown that the transfer from one direct oral anticoagulant (DOACs) to another (with a different mechanism of action), as well as from DOACs to warfarin, can change the state of the blood plasma coagulation system towards both hyper- and hypocoagulation. Unlike standard hemostasis tests, TD can be used to assess the prothrombotic status of a patient with AF and personalized selection of effective anticoagulant therapy.

  • Open Access

    Factors associated with resistance to resolution of left atrial appendage thrombus in patients with atrial fibrillation: 12-month follow-up results

    by A. V. Belokurova, A. V. Mamarina, N. Yu. Khorkova, T. P. Gizatulina, Н. Ю. Хорькова

    Aim. To study the dynamics of left atrial appendage (LAA) thrombosis and to determine the factors associated with resistant LAA thrombus in patients with non-valvular atrial fibrillation (AF) during 12 months of follow-up.Methods. A prospective study included 83 patients with LAA thrombosis detected by transesophageal echocardiography (TEE). The end point was resolution or stability of the thrombus. All patients underwent clinical examination, complete blood count and biochemical blood test, coagulation testing, transthoracic echocardiography (TTE) and TEE.Results. According to the results of TEE, the patients were divided into two groups: group 1 (n=45) with resolution LAA thrombus and group 2 (n=38) with resistant LAA thrombus. Group 2 patients were more likely to take beta-adrenoblockers (57.9% and 31.1%, p=0.014), diuretics (60.5% and 35.6%, p=0.023) and rivaroxaban (39,5% и 13,3%, р=0,010). According to TTE data, group 2 had a higher right atrial volume index (30.7 [24.7; 34.7] vs 24.5 [21.0; 32.2] ml/m2, respectively, p=0.034). Laboratory data analysis showed that group 2 had higher mean platelet volume (MPV) levels (9.1 [8.3; 9.8] vs 8.4 [7.9; 9.4] fl, p=0.035), platelet distribution width (PDW) (15.9 [15.7; 16.2] vs 15.7[15.5; 15.9] %, p=0.007) and platelet large cell ratio (P-LCR) (30.0±9.2 vs 25.3±7.4%, p=0.014).There were significant direct correlations of MPV and P-LCR with the following parameters: right atrial volume, left atrial volumes, pulmonary artery systolic pressure, red blood cell level, hemoglobin level and hematocrit. The inverse association of MPV and P-LCR was with platelet count.Conclusions. Resistance of LAA thrombus to resolution in patients with non-valvular AF is associated with morphofunctional parameters of platelets, which correlate with atrial structural remodeling. The results obtained indicate the need to continue research aimed at studying the contribution of the platelet activity to resistance to LAA thrombus, despite taking oral antocoagulants.

  • Open Access

    The soluble ST2 level predicts risk of atrial fibrillation recurrences in long-term period after radiofrequency ablation

    by Tatiana P. Gizatulina, Aleksandra V. Mamarina, Leysan U. Martyanova, Denis V. Belonogov, Grigoriy V. Kolunin, Tatiana I. Petelina, Nikita E. Shirokov, Elena A. Gorbatenko

    :The hypothesis of the study was the assumption that the serum levels of soluble ST2 (sST2) and growth differentiation factor (GDF-15) can be predictors of atrial fibrillation (AF) recurrence in long-term period after primary radiofrequency catheter ablation (RFA). Of the 165 patients included in the prospective follow-up, the final analysis included 131 patients whose follow-up duration reached 18 months after the end of the blanking period (3 months after RFA). The median age of patients was 59.0 (50.0; 64.0) years, and 80 (61%) were men. Paroxysmal AF was present in 103 (79%) and persistent AF in 28 (21%) patients. All patients underwent transthoracic and transesophageal echocardiography, and electroanatomic mapping was used to assess the area of low-voltage zones (LVZ). sST2 and GDF-15 levels were determined by ELISA using GDF-15/MIC-1 analytical kits (BioVender, Czech Republic) and Presage ST2 (Critical Diagnostics, USA) before RFA. After RFA, patients had regular follow-up visits at 3-6-9-12-18 months with 12-lead ECG or Holter ECG monitoring and with clinical evaluation. The primary endpoint was the occurrence of the first symptomatic AF recurrence (AFr) lasting > 30 s, recorded on an ECG or during daily ECG monitoring, after a blanking period. At the 18-month follow-up, 47 patients (35.9%) had AFr. The groups with and without AFr didn`t differ in the LVZ area. The medians of NT-proBNP, GDF-15 and sST2 also didn`t differ significantly between the groups, but in patients with AFr, the proportion of those with sST2 ≥ 36 ng/ml (the border of the lower and middle terziles) was higher (p = 0.03). According to the one-factor Cox regression analysis, AFr were associated with four factors: AF history ≥ 1 year, early AFr (during the blanking period), left atrial appendage flow velocity (LAAFV) < 54 cm/sec and sST2 ≥ 36 ng/ml. In the multivariate Cox analysis two independent predictors of AFr were obtained: sST2 ≥ 36 ng/ml (HR = 3.8; 95% CI 1.5–9.8, p = 0.006) and LAAFV < 54 сm/sec (HR = 1.96; 95% CI 1.01–3.82, p = 0.048). Serum sST2 level with a cut-off value of 36 ng/ml or more can be used as a predictor of AF recurrence in the long-term period after primary RFA.


  • Open Access

    Left atrial fibrosis as an electroanatomic substrate of atrial fibrillation: possibilities for quantitative assessment

    by A. V. Mamarina, L. U. Martyanova, T. P. Gizatulina

    The article focuses on the role of left atrial (LA) fibrosis as the basis of the electroanatomic substrate in atrial fibrillation (AF), which determines not only the stability of AF but also the success of catheter ablation (CA). In the article the molecular and cellular aspects of LA fibrosis formation and possible mechanisms of arrhythmogenic effects of fibrotic tissue are considered in details, the methods of estimation of LA fibrosis size determining the effectiveness of CA in patients with AF are demonstrated. Current data on the possibilities of using circulating fibrosis biomarkers as predictors of fibrosis severity and recurrence of AF after CA are presented.

  • Open Access

    Principles for diagnosing heart failure with preserved ejection fraction

    by N. E. Shirokov, E. I. Yaroslavskaya, D. V. Krinochkin, N. A. Musikhina, T. P. Gizatulina, T. N. Enina, T. I. Petelina, A. M. Soldatova, E. P. Samoilova, N. O. Pogorelov, et al.

    Low-grade systemic inflammation, myocardial stress, and extracellular matrix fibrosis lead to heart failure with preserved ejection fraction (HFpEF). The HFA-PEFF diagnostic algorithm and the H2FPEF score are recommended for detecting HFpEF. Their low compliance is the reason for improving the methods for diagnosing HFpEF. Modern paraclinical diagnostics of HFpEF includes an assessment of the left ventricular filling pressure during diastolic stress test. Phase analysis of left atrial strain during resting echocardiography may be promising to conclude an increase in mean left atrial pressure. Research interest is growing in relation to biomarkers involved in the regulation of collagen synthesis. Together, paraclinical diagnostics help to characterize sequential morphofunctional cardiac remodeling, increasing the possibility of HFpEF detection.


  • Open Access

    Prediction of low-voltage areas in the left atrium in patients with non-valvular atrial fibrillation by non-invasive markers

    by T. P. Gizatulina, L. U. Martyanova, D. V. Belonogov, A. V. Mamarina, G. V. Kolunin, T. I. Petelina, E. A. Gorbatenko

    Aim. To develop a method for predicting the area of low-voltage area (LVA) in the left atrium (LA), associated with the minimum and maximum expected effectiveness of primary radiofrequency ablation (RFA) in patients with non-valvular atrial fibrillation (AF) using non-invasive predictors.Methods. A longitudinal single-center study included 150 symptomatic non-valvular AF pts aged 20-72 years (median 59.0 [51.0; 64.0]), including 63 women (42%) hospitalized for primary RFA; 119 pts (79.3%) had paroxysmal and 31 (20.7%) - persistent AF. All pts initially underwent general clinical examination, transesophageal and advanced transthoracic echocardiography, estimation of NT-proBNP (pg/ml) and growth differentiation factor 15 (GDF-15, pg/ml) in the blood. Electroanatomical mapping was performed in sinus rhythm before RFA. The area of LVA (50% in all pts.Results. LVA area varied from 0 to 95.3%, median was 13.7% [5.1; 30.9]. Depending on LVA area, pts were divided into 3 groups: 36 pts (30%) in gr. 3. Increase of LVA area was associated with age, presence, and severity of congestive heart failure (CHF), persistent AF, CHA2DS2 -VASc score ≥3 points, increase of LA volume, LV hypertrophy and increase of NT-proBNP and GDF-15 levels. In univariate analysis, LVA area 2). Independent predictors of LVA 2. The model was of good quality, C-statistics was 0.775 (p30 % was associated with age >60 years, NT-proBNP >125 pg/ml, GDF-15 >840 pg/ml, persistent AF, presence of LV hypertrophy, LVEF ≤60%, LA volume index ≥ 32 ml/m2. Independent predictors of LVA >30% were: LA volume index ≥32 ml/m2, GDF-15 >840 pg/ml, and LVEF ≤60%. The model was of good quality, C-statistics was 0.752 (pConclusion. Evaluation of noninvasive parameters, including clinical characteristics, echocardiographic parameters, and blood levels of NT-proBNP and GDF-15, allows prediction of electroanatomical substrate in left atrium in pts with non-valvular AF referred to primary RFA.


  • Open Access

    Validation of a predictive model of the left atrium appendage thrombosis in patients with nonvalvular atrial fibrillation

    by A. V. Belokurova, T. P. Gizatulina, N. Yu. Khorkova, A. V. Mamarina, L. U. Martyanova, E. A. Gorbatenko, Н. Ю. Хорькова

    Aim: To test the previously developed predictive model on a test set, including patients with non-valvular atrial fibrillation (AF).Material and Methods. A predictive model was previously developed on a training set of 638 patients with non-valvular AF. The test set included 175 randomly selected patients with non-valvular AF hospitalized at the Tyumen Cardiology Research Center for radiofrequency ablation (RFA) or electrical cardioversion in 2018-2021. The quality of the predictive model was assessed using ROC analysis.Results. Arterial hypertension, coronary heart disease, congestive chronic heart failure, and persistent AF were more common in patients of both sets with left atrial appendage (LAA) thrombosis. Patients of the training and test sets with LAA thrombus had more pronounced structural changes in the heart cavities and similar changes in the geometry of the heart: normal left ventricle (LV) geometry was less common and eccentric LV hypertrophy was more common. According to the results of a previous retrospective analysis of the data, independent predictors of LAA thrombosis were persistent type of AF, left atrium size, and eccentric LV hypertrophy. Based on the data gathered, a predictive model LAA thrombosis was developed as an equation that includes 3 variables. The cut-off point for calculating the probability of LAA thrombosis is 0.07. Applying this model on a test set showed the good quality of the model: the area under the curve obtained using ROC analysis was 0.750 (p < 0.001). At the same time, the sensitivity and specificity of this model for the detection of LAA thrombosis were 72.3% and 71%, respectively.Conclusion. The evaluation of the quality of the LAA thrombosis predictive model developed on the training set confirmed its good quality on a similar test set of patients with non-valvular AF hospitalized for RFA or electrical cardioversion.

  • Open Access

    Fibroblast growth factor 23 as a predictor of left atrial appendage thrombosis in patients with nonvalvular atrial fibrillation and various risk of stroke

    by T. P. Gizatulina, N. Yu. Khorkova, E. A. Gorbatenko, A. V. Mamarina, T. I. Petelina, L. U. Martyanova, Н. Ю. Хорькова

    Aim. To study the role of fibroblast growth factor 23 (FGF-23) as a predictor of left atrial appendage (LAA) thrombosisin patients (pts) with non-valvular atrial fibrillation (AF) and different risk levels of thromboembolic complications (TEC) according to the CHA2DS2-VASc score.Methods. The study included 250 pts with non-valvular AF hospitalized for radiofrequency ablation, divided into 2 groups: group (gr.) 1 - with 0-1 points (n=79) and gr.2 - with ≥2 points on the CHA2DS2-VASc scale (n=171). According to the results of transesophageal echocardiography, pts of each group were divided into subgroups depending on the presence of LAA thrombosis, which was found in 19 pts of gr.1 and 72 of gr.2. Patients underwent transthoracic echocardiography, determination of blood biomarkers: NT-proBNP (pg/ml), GDF-15 (pg/ml), FGF-23 (pmol/l), highly sensitive C-reactive protein (mg/l), cystatin C (mg/l).Results. Pts with LAA thrombosis in both groups had in common: a longer history of arterial hypertension, a greater proportion of coronary artery disease and persistent AF, lower GFR, higher values of atrial volume indices, left ventricle myocardial mass, systolic pressure in the pulmonary artery, median NT-proBNP, FGF-23 and GDF-15. Logistic regression analysis performed separately in the groups revealed the same independent predictors of LAA thrombosis in both groups: LA volume index (LAVI) and the level of FGF-23 in the blood. At the same time, the threshold value of FGF-23, separating pts by the presence of LAA thrombosis, was higher in gr.1 (≥0.85 and ≥0.5 pmol/l, respectively), and the area under the AUC curve for FGF-23 in gr.1 was greater: 0.964 vs 0.865 in gr.2 (p=0.026).Conclusion. The serum level of FGF-23, along with the LAVI, is an independent predictor of LAA thrombosis in pts with AF and various risk of TEC according to CHA2DS2-VASc; the threshold level of FGF-23 for pts at low risk of TEC is significantly higher than for high risk pts, and allows more accurate prediction of the presence of LAA thrombosis.